prikaz prve stranice dokumenta COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
  Preuzmi
PDF 436.44 KB
Znanstveni rad - Izvorni znanstveni rad
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
Neurology and Therapy, 11 (2022), 2; 741-758. https://doi.org/10.1007/s40120-022-00341-z
Cross, Anne H.; Delgado, Silvia; Habek, Mario; Davydovskaya, Maria; Ward, Brian J.; Cree, Bruce A. C.; Totolyan, Natalia; Pingili, Ratnakar; Mancione, Linda; Hu, Xixi; Sullivan, Roseanne; Su, Wendy; Zielman, Ronald; Gupta, Ayan Das; Montalban, Xavier; Winthrop, Kevin Više autora...

Citirajte ovaj rad

Cross, A. H., Delgado, S., Habek, M., Davydovskaya, M., Ward, B. J., Cree, B. A. C. ... Winthrop, K. (2022). COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurology and Therapy, 11. (2), 741-758. doi: 10.1007/s40120-022-00341-z

Cross, Anne H., et al. "COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab." Neurology and Therapy, vol. 11, br. 2, 2022, str. 741-758. https://doi.org/10.1007/s40120-022-00341-z

Cross, Anne H., Silvia Delgado, Mario Habek, Maria Davydovskaya, Brian J. Ward, Bruce A. C. Cree, Natalia Totolyan, et al. "COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab." Neurology and Therapy 11, br. 2 (2022): 741-758. https://doi.org/10.1007/s40120-022-00341-z

Cross, A. H., et al. (2022) 'COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab', Neurology and Therapy, 11(2), str. 741-758. doi: 10.1007/s40120-022-00341-z

Cross AH, Delgado S, Habek M, Davydovskaya M, Ward BJ, Cree BAC, i sur.. COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab. Neurology and Therapy [Internet]. 06.2022. [pristupljeno 17.10.2024.];11(2):741-758. doi: 10.1007/s40120-022-00341-z

A. H. Cross, et al., "COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab", Neurology and Therapy, vol. 11, br. 2, str. 741-758, Lipanj 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:176399. [Citirano: 17.10.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:176399
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
AutorAnne H. Cross
AutorSilvia Delgado
AutorMario Habek
AutorMaria Davydovskaya
AutorBrian J. Ward
AutorBruce A. C. Cree
AutorNatalia Totolyan
AutorRatnakar Pingili
AutorLinda Mancione
AutorXixi Hu
AutorRoseanne Sullivan
AutorWendy Su
AutorRonald Zielman
AutorAyan Das Gupta
AutorXavier Montalban
AutorKevin Winthrop
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA NEUROLOGIJU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Neurologija
Sažetak (engleski)
Introduction: The SARS-CoV-2 pandemic necessitated better understanding of the impact of disease-modifying therapies on COVID-19 outcomes and vaccination. We report characteristics of COVID-19 cases and vaccination status in ofatumumab-treated relapsing multiple sclerosis (RMS) patients. ----- Methods: COVID-19 data analyzed were from the ongoing, open-label, long-term extension phase 3b ALITHIOS study from December 2019 (pandemic start) and post-marketing cases from August 2020 (ofatumumab first approval) up to 25 September 2021. COVID-19 cases, severity, seriousness, outcomes, vaccination status, and breakthrough infection were evaluated. ------ Results: As of 25 September 2021, 245 of 1703 patients (14.4%) enrolled in ALITHIOS receiving ofatumumab (median exposure: 2.45 years) reported COVID-19 (confirmed: 210; suspected: 35). Most COVID-19 was of mild (44.1%) or moderate (46.5%) severity, but 9% had severe/life-threatening COVID-19. There were 24 serious cases (9.8%) with 23 patients hospitalized; 22 recovered and 2 died. At study cut-off, 241 patients (98.4%) had recovered or were recovering or had recovered with sequelae and 2 (0.8%) had not recovered. Ofatumumab was temporarily interrupted in 39 (15.9%) patients. Before COVID-19 onset, IgG levels were within the normal range in all COVID-19-affected patients, while IgM was < 0.4 g/l in 23 (9.4%) patients. No patient had a reinfection. Overall, 559 patients were vaccinated (full, 476; partial, 74; unspecified, 9). Breakthrough infection was reported in 1.5% (7/476) patients, and 11 reported COVID-19 after partial vaccination. As of 25 September 2021, the Novartis Safety Database (~ 4713 patient-treatment years) recorded 90 confirmed COVID-19 cases receiving ofatumumab. Most cases were non-serious (n = 80), and ten were serious (1 medically significant, 9 hospitalized, 0 deaths). Among 36 of 90 cases with outcomes reported, 30 recovered and 6 did not recover. ----- Conclusion: COVID-19 in RMS patients on ofatumumab was primarily of mild/moderate severity and non-serious in these observational data. Most recovered from COVID-19 without treatment interruption. Two people died with COVID-19. Breakthrough COVID-19 despite being fully/partially vaccinated was uncommon.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaNeurology and Therapy
Brojčani podacivol. 11, br. 2, str. 741-758
p-ISSN2193-8253
e-ISSN2193-6536
DOIhttps://doi.org/10.1007/s40120-022-00341-z
URN:NBNurn:nbn:hr:105:176399
Datum objave publikacije2022-06
URL dokumentahttps://link.springer.com/10.1007/s40120-022-00341-z
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno 4.0 međunarodna (CC BY-NC 4.0)
Datum i vrijeme pohrane2022-10-03 07:10:03